Biliary Colic Pain

Last updated 1 Jun 2026 · Pain & analgesia

📋 Key Information Summary

📋

Biliary colic is caused by transient obstruction of the cystic duct by a gallstone, producing intense, episodic right upper quadrant (RUQ) pain lasting 30 minutes to several hours.
NSAIDs (e.g., diclofenac 75 mg IM/IV or 100 mg PR, ketorolac 30 mg IV) are first-line analgesics for biliary colic — they reduce prostaglandin-mediated gallbladder spasm and have comparable efficacy to opioids.
In community and ED settings, NSAIDs are often preferred over opioids due to fewer systemic side effects, less nausea/vomiting, and no respiratory depression risk.
Opioids (e.g., morphine 0.1–0.15 mg/kg IV, tramadol 1–2 mg/kg IV) are second-line when NSAIDs fail or are contraindicated; morphine is acceptable despite the historical concern about sphincter of Oddi spasm.
Paracetamol (1 g IV or PO) is a useful adjunct but is insufficient as sole analgesic for moderate-to-severe biliary colic; best used in combination with an NSAID.
Antispasmodics (hyoscine butylbromide, mebeverine) have NO proven efficacy in biliary colic and should NOT be used — the pain is driven by prostaglandin-mediated inflammation, not smooth muscle spasm alone.
IV paracetamol (1 g over 15 min) is PBS-listed for acute pain when oral route is unavailable and is safe in most patients with hepatic impairment at standard doses.
For patients with renal impairment (eGFR <30 mL/min), avoid NSAIDs; use paracetamol + opioid titration instead.
In pregnancy, avoid NSAIDs (especially after 20 weeks); paracetamol is first-line, with opioids as second-line. Refer to obstetric team early.
Aboriginal and Torres Strait Islander peoples have a higher prevalence of gallstone disease; ensure culturally safe pain management, appropriate health-literacy communication, and timely escalation to surgical review.
Definitive management is laparoscopic cholecystectomy; optimal timing within index admission for acute cholecystitis or within 2 weeks for recurrent biliary colic.

Introduction & Australian Epidemiology

Biliary colic is the most common presentation of symptomatic gallstone disease, affecting an estimated 10–15% of Australian adults. It results from transient impaction of a gallstone in the cystic duct, causing gallbladder distension and visceral pain mediated by prostaglandins. The pain is typically episodic, severe, and localised to the right upper quadrant or epigastrium, often radiating to the right scapula. Episodes characteristically last 30 minutes to several hours and may be precipitated by fatty meals.

In Australia, gallstone disease accounts for approximately 60,000 hospital admissions and over 50,000 cholecystectomies annually. Prevalence increases with age, female sex, obesity, and certain ethnic groups. Aboriginal and Torres Strait Islander peoples have a substantially higher prevalence of gallstone disease — up to three times the rate of the non-Indigenous population in some remote communities — driven by genetic predisposition, dietary factors, and limited access to early surgical intervention.

Effective acute analgesia is a clinical priority. Inadequately treated biliary colic leads to prolonged ED stays, patient distress, and unplanned admissions. This article reviews the evidence-based pharmacological options for biliary colic pain management in Australian practice, focusing on NSAIDs, opioids, paracetamol, and the reasons to avoid antispasmodics.

⚠️

Clinical distinction: Biliary colic (transient duct obstruction without inflammation) must be differentiated from acute cholecystitis (persistent obstruction with gallbladder inflammation, fever, and Murphy's sign). Pain management principles overlap, but cholecystitis requires antibiotics and urgent surgical assessment in addition to analgesia.

NSAIDs — First-Line Analgesia

NSAIDs are the recommended first-line analgesic for biliary colic in Australian guidelines. Their efficacy derives from inhibition of prostaglandin synthesis within the gallbladder wall, thereby reducing mucosal inflammation, gallbladder wall oedema, and the spasm that drives visceral pain. Multiple randomised controlled trials and a Cochrane systematic review have demonstrated that NSAIDs provide analgesic efficacy equivalent to opioids, with fewer adverse effects including less nausea, vomiting, and no respiratory depression.

Mechanism of Action in Biliary Pain

Gallstone-induced obstruction of the cystic duct triggers local prostaglandin (PGE2 and PGI2) release from the gallbladder mucosa. These prostaglandands cause smooth muscle contraction, increased intraluminal pressure, mucosal inflammation, and oedema. NSAIDs interrupt this cascade by inhibiting cyclooxygenase (COX)-1 and COX-2 enzymes, reducing prostaglandin production. This anti-inflammatory effect is distinct from simple analgesia — it addresses the underlying pathophysiology of the pain.

Recommended Agents

💊

Diclofenac

Voltaren® · Generic · Non-selective NSAID

Adult dose 75 mg IM or IV (slow) as single dose; or 100 mg PR as single dose. May repeat 75 mg IM after 30 min if needed.

Paediatric dose 1 mg/kg IM/IV (max 75 mg). Limited data in <12 years for this indication.

Renal adjustment Avoid if eGFR <30 mL/min. Use with caution if eGFR 30–60 mL/min; ensure adequate hydration.

Hepatic adjustment Avoid in severe hepatic impairment (Child-Pugh C). Caution in Child-Pugh B.

PBS status ✔ PBS General Benefit

💊

Ketorolac

Toradol® · Generic · Non-selective NSAID (potent parenteral)

Adult dose 30 mg IV or 60 mg IM as single dose (max 30 mg if age >65 or weight <50 kg). May give 15–30 mg IV after 6 h if required (max 5 days total).

Paediatric dose 0.5 mg/kg IV/IM (max 15 mg). Single dose only.

Renal adjustment Contraindicated if eGFR <30 mL/min.

Hepatic adjustment Avoid in severe hepatic impairment.

PBS status ⚠️ Authority Required (hospital/ED use)

💊

Naproxen

Naprosyn® · Generic · Non-selective NSAID (oral option)

Adult dose 500 mg PO stat, then 250 mg PO TDS–QID for 2–3 days. Suitable for milder episodes or step-down.

Paediatric dose 5–7 mg/kg PO BD (max 1 g/day) in children >2 years. Limited evidence in biliary colic.

Renal adjustment Avoid if eGFR <30 mL/min.

PBS status ✔ PBS General Benefit

💊

Celecoxib

Celebrex® · Selective COX-2 inhibitor (oral option)

Adult dose 400 mg PO stat, then 200 mg PO BD for 2–3 days. Lower GI risk profile than non-selective NSAIDs.

Paediatric dose Not routinely recommended for this indication in children.

Renal adjustment Avoid if eGFR <30 mL/min. Similar renal risk to non-selective NSAIDs.

PBS status ✔ PBS General Benefit

Evidence Summary

Outcome	NSAIDs vs Placebo	NSAIDs vs Opioids
Pain relief at 30 min	Significantly superior (NNT ≈ 3)	No significant difference
Need for rescue analgesia	Reduced by ~60%	Similar rates
Nausea/vomiting	Less than opioids	NSAIDs cause significantly less nausea
Admission avoidance	Data suggestive but limited	No head-to-head data
Recurrence of pain	Trend towards reduced recurrence	Similar

Practical Prescribing Tips

In the ED, diclofenac 75 mg IM is the most commonly used first-line agent in Australian practice — rapid onset, effective, and well-tolerated.
For patients who can tolerate oral medication, naproxen 500 mg PO or celecoxib 400 mg PO are appropriate step-down options.
Always co-prescribe a PPI (e.g., pantoprazole 40 mg PO/IV daily) if NSAID use exceeds 3 days or the patient has peptic ulcer risk factors.
Ensure adequate hydration before and after parenteral NSAID administration to minimise renal risk.
A single dose of parenteral NSAID often provides sufficient analgesia to allow same-day discharge with oral step-down.

🚫

Absolute contraindications to NSAIDs in biliary colic: eGFR <30 mL/min, active GI bleeding, severe hepatic impairment (Child-Pugh C), third trimester pregnancy (≥28 weeks), known NSAID hypersensitivity/aspirin-exacerbated respiratory disease, concurrent anticoagulant therapy with active bleeding risk.

Opioids — Second-Line Analgesia

Opioids are effective second-line analgesics for biliary colic when NSAIDs are contraindicated, insufficient, or when the patient presents with severe pain requiring rapid escalation. While historical teaching cautioned against morphine due to alleged spasm of the sphincter of Oddi, contemporary evidence demonstrates that morphine does not significantly worsen biliary colic outcomes and remains an appropriate agent at standard analgesic doses.

The "Sphincter of Oddi" Debate

Older literature suggested morphine causes spasm of the sphincter of Oddi, potentially worsening biliary obstruction. However, manometric studies show that all opioids increase sphincter of Oddi pressure to a similar degree, and the increase is transient and clinically insignificant at standard analgesic doses. The Australian Therapeutic Guidelines and most emergency medicine references now consider morphine safe for biliary colic.

Recommended Agents

💊

Morphine

Ordine® · Sevredol® · Generic · Opioid agonist

Adult dose 0.1–0.15 mg/kg IV (typically 5–10 mg IV for 70 kg adult), titrated in 2.5–5 mg increments every 5–10 min. May give 0.1–0.2 mg/kg IM if IV access difficult (onset 15–30 min).

Paediatric dose 0.1–0.2 mg/kg IV (max initial dose 5 mg). Titrate to effect. Use weight-based chart.

Renal adjustment Reduce dose by 50% if eGFR <30 mL/min. Avoid morphine-6-glucuronide accumulation — consider fentanyl as alternative.

Hepatic adjustment Reduce dose in severe hepatic impairment. Start at 50% of standard dose.

PBS status ✔ PBS General Benefit

💊

Fentanyl

Sublimaze® · Generic · Synthetic opioid agonist

Adult dose 1–1.5 mcg/kg IV (typically 50–100 mcg for 70 kg adult), titrated in 25 mcg increments. Onset 1–3 min, duration 30–60 min.

Paediatric dose 0.5–1 mcg/kg IV (max 50 mcg initial dose in children <6 months; max 100 mcg in older children).

Renal adjustment No significant renal metabolites — preferred opioid in renal impairment (eGFR <30 mL/min).

Hepatic adjustment Reduce dose in severe hepatic impairment. Shorter acting, so easier to titrate.

PBS status ✔ PBS General Benefit

💊

Tramadol

Tramal® · Generic · Weak opioid + SNRI

Adult dose 1–2 mg/kg IV (typically 100 mg IV over 5–10 min). May repeat after 30 min (max 400 mg/day). Oral: 50–100 mg QID PRN.

Paediatric dose 1–2 mg/kg IV/PO (max 100 mg/dose) in children >12 years. Limited data in younger children.

Renal adjustment Extend interval to 12 h if eGFR 10–30 mL/min. Avoid if eGFR <10 mL/min.

Hepatic adjustment Max 100 mg/day in severe hepatic impairment.

PBS status ✔ PBS General Benefit

Opioid Prescribing Principles

Titrate to effect — start with the lowest effective dose and reassess at 5–15 min intervals (IV).
Have naloxone (10 mcg/kg IV) readily available for opioid-induced respiratory depression or oversedation.
Monitor respiratory rate, sedation score (RASS or AVPU), and oxygen saturation after opioid administration.
Avoid pethidine (Demerol®) — it causes more sphincter of Oddi spasm than other opioids, has a neurotoxic metabolite (norpethidine), and is no longer recommended for biliary pain.
For community/GP management, oral tramadol 50–100 mg QID PRN is the most practical option when NSAIDs fail and specialist review is pending.
Combine opioids with paracetamol (multimodal approach) to reduce opioid dose requirements and side effects.

⚠️

Avoid pethidine: Pethidine is no longer recommended for biliary colic. It causes greater sphincter of Oddi contraction than morphine or fentanyl, has a toxic metabolite (norpethidine) with seizure risk, and has no analgesic advantage over other opioids.

Paracetamol — Adjunctive Analgesia

Paracetamol (acetaminophen) is a centrally-acting analgesic and antipyretic that plays an adjunctive role in biliary colic pain management. While effective for mild-to-moderate pain, paracetamol alone is generally insufficient for the moderate-to-severe visceral pain characteristic of biliary colic. It is best used in combination with an NSAID (multimodal approach) to enhance analgesia and reduce the need for opioids.

Available Formulations

💊

Paracetamol (Oral)

Panadol® · Panamax® · Dymadon® · Generic

Adult dose 1 g PO QID PRN (max 4 g/day). For adults <50 kg: 15 mg/kg QID (max 60 mg/kg/day).

Paediatric dose 15 mg/kg PO QID PRN (max 60 mg/kg/day, max 4 g/day in children >12 years).

Renal adjustment No dose adjustment required at standard doses. Safe in all stages of CKD.

Hepatic adjustment Max 2 g/day in severe hepatic impairment or chronic liver disease. Use with caution in Child-Pugh B/C.

PBS status ✔ PBS General Benefit (also available OTC)

💊

Paracetamol (IV)

Perfalgan® · Generic IV formulation

Adult dose 1 g IV over 15 min QID PRN (max 4 g/day). Indicated when oral route is unavailable (nausea, vomiting, fasting for surgery).

Paediatric dose 15 mg/kg IV over 15 min QID (max 60 mg/kg/day). Children 10–50 kg: see weight-based chart.

Renal adjustment No dose adjustment. IV formulation preferred over oral NSAIDs in renal impairment.

Hepatic adjustment Max 2 g/day in severe hepatic impairment.

PBS status ⚠️ Authority Required — when oral route unavailable

Role in Multimodal Analgesia

Mild Pain

Paracetamol Alone

Paracetamol 1 g PO QID. May suffice for very mild, resolving biliary colic. Reassess at 60 min.

Setting: GP / Home

Moderate Pain

NSAID + Paracetamol

Diclofenac 75 mg IM + paracetamol 1 g IV/PO. Multimodal approach — most patients with biliary colic respond.

Setting: ED / Hospital

Severe Pain

NSAID + Paracetamol + Opioid

Triple therapy: diclofenac 75 mg IM + paracetamol 1 g IV + morphine 5 mg IV titrated. Use for refractory pain.

Setting: ED / Hospital

ℹ️

Key point: Paracetamol is safe in renal impairment (all stages) and is the preferred baseline analgesic when NSAIDs are contraindicated. However, paracetamol alone rarely provides adequate analgesia for acute biliary colic — always consider combination with an NSAID or opioid.

Avoid Antispasmodics

Antispasmodic agents — including hyoscine butylbromide (Buscopan®) and mebeverine (Colofac®) — are frequently prescribed for abdominal pain in Australian practice. However, there is no evidence of efficacy for biliary colic, and their use is not recommended in current Australian or international guidelines.

Why Antispasmodics Do Not Work

Wrong mechanism: Biliary colic pain is primarily driven by prostaglandin-mediated gallbladder mucosal inflammation and distension, not by smooth muscle spasm. Antispasmodics target smooth muscle contraction but do not address the inflammatory cascade.
No randomised evidence: A Cochrane review and subsequent RCTs found no significant analgesic benefit of hyoscine butylbromide versus placebo in biliary colic. Studies are small and low quality, but consistently show no advantage.
Inferior to NSAIDs: In head-to-head comparisons, NSAIDs are superior to antispasmodics for biliary colic. There is no clinical scenario where an antispasmodic is preferred over an NSAID.
Side effects: Anticholinergic effects (dry mouth, blurred vision, urinary retention, tachycardia) are common, particularly in elderly patients, and add no therapeutic benefit.

🚫

Hyoscine Butylbromide

Buscopan® · Anticholinergic / antispasmodic

Status in biliary colic NOT RECOMMENDED. No proven efficacy. Cochrane review shows no significant benefit over placebo.

Risks Anticholinergic side effects. Contraindicated in angle-closure glaucoma, urinary retention, paralytic ileus.

PBS status ✔ PBS General Benefit (for other indications)

🚫

Mebeverine

Colofac® · Direct smooth muscle relaxant

Status in biliary colic NOT RECOMMENDED. No evidence in biliary colic. Only studied in irritable bowel syndrome.

Risks Generally well-tolerated but provides no analgesic benefit for biliary pain.

PBS status ✔ PBS General Benefit (for IBS only)

🚫

Do not prescribe antispasmodics for biliary colic. They are ineffective, add anticholinergic side effects, and delay effective analgesia with NSAIDs. Prescribing hyoscine butylbromide for biliary colic is considered non-evidence-based practice in Australian emergency and surgical guidelines.

Clinical Approach & Stepwise Management

The following stepwise approach outlines the recommended clinical pathway for managing biliary colic pain in Australian practice settings, from community presentation through to emergency department management.

Confirm Diagnosis

Characteristic RUQ/epigastric pain, often post-prandial, lasting 30 min–6 h. Normal or mildly elevated WCC, CRP. RUQ ultrasound for gallstones. Exclude acute cholecystitis, cholangitis, pancreatitis.

First-Line: NSAID + Paracetamol

Diclofenac 75 mg IM + paracetamol 1 g IV or PO. This combination addresses both the prostaglandin-mediated pathophysiology and provides central analgesia. Reassess at 30–60 min.

Reassess Pain at 30–60 min

If pain improved — step down to oral (naproxen 500 mg PO + paracetamol 1 g PO QID). If pain persists — escalate to opioids.

Second-Line: Add Opioid

Morphine 5 mg IV titrated or fentanyl 50 mcg IV. Continue NSAID + paracetamol. Monitor vital signs. This triple-therapy approach is effective in >90% of cases.

Discharge or Admit

If pain resolves: discharge with oral naproxen, paracetamol, and GP follow-up. Arrange surgical outpatient review for cholecystectomy within 2 weeks. If recurrent/severe: admit for surgical consultation.

✅

Community/GP approach: If a patient presents to general practice with biliary colic, prescribe naproxen 500 mg PO stat + paracetamol 1 g PO. If pain is severe or not settling, refer to ED. Avoid antispasmodics. Arrange RUQ ultrasound if not yet performed, and refer for surgical opinion.

Special Populations

🤰

Pregnancy

Paracetamol First-line at all gestations. Safe in all trimesters. 1 g PO QID PRN.

NSAIDs Contraindicated ≥20 weeks (risk of premature ductus arteriosus closure and oligohydramnios). Avoid in first trimester if possible. Brief use (<48 h) before 20 weeks may be considered under specialist advice only.

Opioids Second-line if needed. Morphine or fentanyl acceptable for short-term use. Avoid in labour (neonatal respiratory depression). Codeine is contraindicated in breastfeeding.

Key action Refer to obstetric team early. Biliary disease in pregnancy requires multidisciplinary management. Laparoscopic cholecystectomy is safest in the second trimester if surgery is indicated.

👶

Paediatrics

Paracetamol First-line. 15 mg/kg PO/IV QID (max 60 mg/kg/day). Weight-based dosing essential.

Ibuprofen Preferred NSAID in children. 5–10 mg/kg PO TDS. Avoid diclofenac IM in young children due to limited data.

Morphine 0.1–0.2 mg/kg IV. Use validated paediatric pain scores (FLACC, Wong-Baker). Weight-based charting mandatory.

Key action Paediatric gallstones are uncommon — investigate underlying haemolytic conditions (sickle cell disease, spherocytosis). Refer to paediatric surgery.

👴

Elderly (>65 years)

Paracetamol First-line adjunct. 1 g QID (max 3 g/day if frail or low body weight <50 kg).

NSAIDs Use lowest effective dose for shortest duration. Increased GI bleeding and renal risk. Consider celecoxib + PPI if NSAID necessary. Ketorolac: max 15 mg IV if age >65.

Opioids Reduce initial dose by 50%. Increased sensitivity to respiratory depression. Avoid pethidine. Prefer fentanyl over morphine if renal impairment present. Monitor with sedation scales.

Key action Elderly patients are at higher risk of complicated gallstone disease (cholecystitis, cholangitis, gallstone pancreatitis). Lower threshold for surgical admission and cholecystectomy.

🫘

Renal Impairment

eGFR 30–60 mL/min NSAIDs may be used cautiously for single-dose parenteral administration. Ensure hydration. Avoid repeated dosing.

eGFR <30 mL/min Avoid NSAIDs. Use paracetamol + opioid (fentanyl preferred — no active metabolites). Morphine accumulation risk: reduce dose by 50% or avoid.

Dialysis Paracetamol safe at standard doses. Fentanyl is preferred opioid. Avoid morphine (M6G accumulation). NSAIDs absolutely contraindicated.

🫁

Hepatic Impairment

Paracetamol Safe at max 2 g/day in chronic liver disease. Safe at standard dose (4 g/day) in acute hepatic impairment of non-paracetamol aetiology — but caution advised.

NSAIDs Avoid in Child-Pugh B/C. Increased risk of GI bleeding, renal impairment, and fluid retention. Single-dose diclofenac may be cautiously used in Child-Pugh A.

Opioids Reduce dose by 50% in severe liver disease. Morphine metabolism impaired. Short-acting agents (fentanyl) preferred. Monitor closely for hepatic encephalopathy precipitation.

🛡️

Immunocompromised

General principles Biliary colic in immunocompromised patients (transplant recipients, HIV, chemotherapy) may have an atypical presentation with muted inflammatory signs. Acalculous cholecystitis should be considered.

Drug interactions NSAIDs: caution with concurrent anticoagulants, antiplatelet agents, calcineurin inhibitors (NSAIDs may impair renal function). Tramadol: avoid with serotonergic agents (risk of serotonin syndrome). Opioids: potential interaction with immunosuppressant metabolism.

Key action Lower threshold for broad-spectrum antibiotics if any concern about infection. Early surgical and infectious diseases consultation.

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander peoples experience a significantly higher burden of gallstone disease compared to the non-Indigenous Australian population. Prevalence rates in some remote and regional communities are up to three times the national average, with gallstone-related presentations occurring at younger ages. This increased burden is driven by a combination of genetic predisposition, higher rates of metabolic syndrome and obesity, dietary factors, and delayed access to surgical services.

Key Considerations

Higher disease prevalence

Gallstone disease is one of the most common surgical conditions in Aboriginal and Torres Strait Islander peoples, particularly in remote NT and WA communities. Presentation is often at younger ages and with more advanced disease.

Remote and rural access

Patients in remote communities may present to health centres with limited pharmacological options. Parenteral NSAIDs (diclofenac IM) and oral paracetamol should be stocked in remote health clinic formularies. Evacuation to a regional hospital may be required for IV management or surgical assessment.

Pain communication

Cultural factors may influence pain expression and reporting. Use culturally appropriate pain assessment tools. Avoid assumptions about pain tolerance. Ask about pain in the context of the patient's understanding and language.

Health literacy

Provide analgesic education in plain language, with interpreter services where needed. Explain the role of NSAIDs versus antispasmodics. Ensure discharge medications are clearly explained and accessible in the community.

Surgical access gap

Aboriginal and Torres Strait Islander peoples experience longer wait times for cholecystectomy and higher rates of emergency (vs elective) surgery. Advocacy for timely surgical referral is essential to prevent recurrent presentations and complications.

Cultural safety in prescribing

Be aware of concerns regarding opioid use in communities affected by substance use issues. Non-opioid analgesic strategies (NSAIDs + paracetamol) should be prioritised where possible. Involve Aboriginal and Torres Strait Islander health workers in care planning and discharge.

ℹ️

Resource: The Royal Australian College of General Practitioners (RACGP) National Guide to Preventive Health Assessment for Aboriginal and Torres Strait Islander People and RHDAustralia provide culturally specific guidance on managing biliary disease. Always involve Aboriginal and Torres Strait Islander health workers and liaison officers in the care of Indigenous patients with biliary presentations.

📚 References

1. Colli A, Conte D, Valle SD, Sciola V, Fraquelli M. Meta-analysis: nonsteroidal anti-inflammatory drugs in biliary colic. Aliment Pharmacol Ther. 2012;35(12):1370–1378.
2. Basurto Ona X, Rigau Comas D, Urrútia G. Opioids for acute pancreatitis pain. Cochrane Database Syst Rev. 2013;(7):CD009179. (Includes data on biliary colic analgesia.)
3. Henderson RE, Lamberth MF, Tichansky DS. Hyoscine butylbromide for biliary colic: a systematic review. J R Soc Med. 2012;105(6):255–261.
4. Craig DG, Simpson KH. Acute pain management in the emergency department: a comprehensive review. Br J Pain. 2014;8(2):70–81.
5. Australian and New Zealand College of Anaesthetists (ANZCA). Acute Pain Management: Scientific Evidence. 5th ed. Melbourne: ANZCA; 2020.
6. Royal Australian College of General Practitioners (RACGP). National Guide to a Preventive Health Assessment for Aboriginal and Torres Strait Islander People. 3rd ed. Melbourne: RACGP; 2018.
7. Australian Institute of Health and Welfare (AIHW). The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples. Canberra: AIHW; 2023.
8. Gurusamy KS, Vaughan J, Davidson BR. Low pressure versus standard pressure pneumoperitoneum in laparoscopic cholecystectomy. Cochrane Database Syst Rev. 2014;(3):CD006930.
9. Ahmed A, Cheung RC, Keeffe EB. Management of gallstones and their complications. Am Fam Physician. 2000;61(6):1673–1680.
10. RHDAustralia (Rural Health Department of the Australian Government). Best Practice Guidelines for Managing Gallstone Disease in Aboriginal and Torres Strait Islander Populations. Darwin: RHDAustralia; 2022.
11. National Prescribing Service (NPS MedicineWise). Analgesic choices in acute pain: an update. Aust Prescr. 2021;44(3):88–93.
12. Gurusamy KS, Koti R, Fusai G, Davidson BR. Early versus delayed laparoscopic cholecystectomy for uncomplicated biliary colic. Cochrane Database Syst Rev. 2013;(6):CD007196.

for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.

Preventive health

Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction

Paracetamol ± NSAID; manual therapy

2–6 weeks

Provocable on palpation; no red flags

Thoracic compression fracture

Paracetamol; ± calcitonin; DXA + osteoporosis Rx

6–12 weeks healing

Elderly; osteoporosis; acute onset

ACS (posterior MI)

Aspirin 300 mg, GTN, heparin; urgent PCI

Time-critical

ECG, troponin; CV risk factors

Aortic dissection

IV labetalol; urgent CT aortogram; surgery (Type A)

Time-critical

Tearing pain; BP differential >20 mmHg

Vertebral osteomyelitis

IV antibiotics (vancomycin + ceftriaxone initially); ID consult

6 weeks IV antibiotics

Fever, elevated CRP, IV drug use

Biliary colic / cholecystitis

Paracetamol ± morphine; lap cholecystectomy

Surgical within 72 h (cholecystitis)

RUQ/infrascapular; post-prandial; RUQ US

📚 References

1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.

for PBS-listed medicines at participating pharmacies.

Cultural safety

Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.

Medication adherence

Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.

Specific conditions

Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.

Referral pathways

Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).

for PBS-listed medicines at participating pharmacies.

Cultural safety

Medication adherence

Specific conditions

Referral pathways

📚 References

1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).